<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39329149</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2162-2531</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Molecular therapy. Nucleic acids</Title><ISOAbbreviation>Mol Ther Nucleic Acids</ISOAbbreviation></Journal><ArticleTitle>Cell-targeted gene modification by delivery of CRISPR-Cas9 ribonucleoprotein complexes in pseudotyped lentivirus-derived nanoparticles.</ArticleTitle><Pagination><StartPage>102318</StartPage><MedlinePgn>102318</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102318</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omtn.2024.102318</ELocationID><Abstract><AbstractText>To fully utilize the potential of CRISPR-Cas9-mediated genome editing, time-restricted and targeted delivery is crucial. By modulating the pseudotype of engineered lentivirus-derived nanoparticles (LVNPs), we demonstrate efficient cell-targeted delivery of Cas9/single guide RNA (sgRNA) ribonucleoprotein (RNP) complexes, supporting gene modification in a defined subset of cells in mixed cell populations. LVNPs pseudotyped with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein resulted in angiotensin-converting enzyme 2 (ACE2)-dependent insertion or deletion (indel) formation in an ACE2<sup>+</sup>/ACE2<sup>-</sup> population of cells, whereas Nipah virus glycoprotein pseudotyping resulted in Ephrin-B2/B3-specific gene knockout. Additionally, LVNPs pseudotyped with Edmonston strain measles virus glycoproteins (MV-H/F) delivered Cas9/sgRNA RNPs to CD46<sup>+</sup> cells with and without additional expression of SLAM (signaling lymphocytic activation molecule; CD150). However, an engineered SLAM-specific measles virus pseudotype (measles virus-hemagglutinin/fusion [MV-H/F]-SLAM) efficiently targeted LVNPs to SLAM<sup>+</sup> cells. Lentiviral vectors (LVs) pseudotyped with MV-H/F-SLAM efficiently transduced &gt;80% of interleukin (IL)-4/IL-21-stimulated primary B cells cultured on CD40 ligand (CD40L)-expressing feeder cells. Notably, LVNPs pseudotyped with MV-H/F and MV-H/F-SLAM reached indel rates of &gt;80% and &gt;60% in stimulated primary B cells, respectively. Collectively, our findings demonstrate the modularity of LVNP-directed delivery of ready-to-function Cas9/sgRNA complexes. Using a panel of different pseudotypes, we provide evidence that LVNPs can be engineered to induce effective indel formation in a subpopulation of cells defined by the expression of surface receptors.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Ian Helstrup</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovsing</LastName><ForeName>Anne Bruun</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janns</LastName><ForeName>Jacob Hørlück</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomsen</LastName><ForeName>Emil Aagaard</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruzo</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sana Biotechnology, Inc, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bøggild</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Interdisciplinary Nanoscience Center (iNANO), Aarhus University, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nedergaard</LastName><ForeName>Frederikke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Møller</LastName><ForeName>Charlotte Thornild</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boesen</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Interdisciplinary Nanoscience Center (iNANO), Aarhus University, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Degn</LastName><ForeName>Søren Egedal</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Jagesh V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Sana Biotechnology, Inc, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikkelsen</LastName><ForeName>Jacob Giehm</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Nucleic Acids</MedlineTA><NlmUniqueID>101581621</NlmUniqueID><ISSNLinking>2162-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Delivery</Keyword><Keyword MajorTopicYN="N">Gag</Keyword><Keyword MajorTopicYN="N">LVNP</Keyword><Keyword MajorTopicYN="N">cell-targeted gene modification</Keyword><Keyword MajorTopicYN="N">primary B-cells</Keyword><Keyword MajorTopicYN="N">pseudotyping</Keyword><Keyword MajorTopicYN="N">virus-like particle, VLP, CRISPR-Cas9</Keyword></KeywordList><CoiStatement>J.G.M. is a member of the scientific advisory board of Nvelop Therapeutics. The company was not involved in the present study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39329149</ArticleId><ArticleId IdType="pmc">PMC11426049</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2024.102318</ArticleId><ArticleId IdType="pii">S2162-2531(24)00205-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barrangou R., Fremaux C., Deveau H., Richards M., Boyaval P., Moineau S., Romero D.A., Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315:1709–1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">17379808</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286148</ArticleId><ArticleId IdType="pubmed">22745249</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedenheft B., Sternberg S.H., Doudna J.A. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482:331–338. doi: 10.1038/nature10886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10886</ArticleId><ArticleId IdType="pubmed">22337052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali P., Esvelt K.M., Church G.M. Cas9 as a versatile tool for engineering biology. Nat. Methods. 2013;10:957–963. doi: 10.1038/nmeth.2649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2649</ArticleId><ArticleId IdType="pmc">PMC4051438</ArticleId><ArticleId IdType="pubmed">24076990</ArticleId></ArticleIdList></Reference><Reference><Citation>Young L.S., Searle P.F., Onion D., Mautner V. Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 2006;208:299–318. doi: 10.1002/path.1896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1896</ArticleId><ArticleId IdType="pubmed">16362990</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery. J. Virol. 1998;72:9873–9880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110499</ArticleId><ArticleId IdType="pubmed">9811723</ArticleId></ArticleIdList></Reference><Reference><Citation>Naldini L., Blömer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–267.</Citation><ArticleIdList><ArticleId IdType="pubmed">8602510</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff J.H., Mikkelsen J.G. Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years. J. Biomed. Sci. 2022;29:79. doi: 10.1186/s12929-022-00865-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-022-00865-4</ArticleId><ArticleId IdType="pmc">PMC9548131</ArticleId><ArticleId IdType="pubmed">36209077</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki T., Miyauchi K., Urano E., Ichikawa R., Komano J. Protein transduction by pseudotyped lentivirus-like nanoparticles. Gene Ther. 2011;18:936–941. doi: 10.1038/gt.2011.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2011.38</ArticleId><ArticleId IdType="pubmed">21451580</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmiryan A., Basmaciogullari S., Henry A., Paques F., Danos O. Efficient gene targeting mediated by a lentiviral vector-associated meganuclease. Nucleic Acids Res. 2011;39:7610–7619. doi: 10.1093/nar/gkr524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr524</ArticleId><ArticleId IdType="pmc">PMC3177226</ArticleId><ArticleId IdType="pubmed">21715375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Bak R.O., Krogh L.B., Staunstrup N.H., Moldt B., Corydon T.J., Schrøder L.D., Mikkelsen J.G. DNA transposition by protein transduction of the piggyBac transposase from lentiviral Gag precursors. Nucleic Acids Res. 2014;42 doi: 10.1093/nar/gkt1163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1163</ArticleId><ArticleId IdType="pmc">PMC3936723</ArticleId><ArticleId IdType="pubmed">24270790</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Bak R.O., Mikkelsen J.G. Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases. Elife. 2014;3 doi: 10.7554/eLife.01911.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.01911</ArticleId><ArticleId IdType="pmc">PMC3996624</ArticleId><ArticleId IdType="pubmed">24843011</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Laustsen A., Zhou Y., Sun C., Anderson M.V., Li S., Uldbjerg N., Luo Y., Jakobsen M.R., Mikkelsen J.G. Targeted, homology-driven gene insertion in stem cells by ZFN-loaded 'all-in-one' lentiviral vectors. Elife. 2016;5 doi: 10.7554/eLife.12213.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.12213</ArticleId><ArticleId IdType="pmc">PMC4900802</ArticleId><ArticleId IdType="pubmed">27278774</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J.G., Dang Y., Abraham S., Ma H., Zhang J., Guo H., Cai Y., Mikkelsen J.G., Wu H., Shankar P., Manjunath N. Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther. 2016;23:627–633. doi: 10.1038/gt.2016.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2016.27</ArticleId><ArticleId IdType="pubmed">27052803</ArticleId></ArticleIdList></Reference><Reference><Citation>Skipper K.A., Nielsen M.G., Andersen S., Ryø L.B., Bak R.O., Mikkelsen J.G. Time-Restricted PiggyBac DNA Transposition by Transposase Protein Delivery Using Lentivirus-Derived Nanoparticles. Mol. Ther. Nucleic Acids. 2018;11:253–262. doi: 10.1016/j.omtn.2018.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2018.02.006</ArticleId><ArticleId IdType="pmc">PMC5992343</ArticleId><ArticleId IdType="pubmed">29858060</ArticleId></ArticleIdList></Reference><Reference><Citation>Indikova I., Indik S. Highly efficient 'hit-and-run' genome editing with unconcentrated lentivectors carrying Vpr.Prot.Cas9 protein produced from RRE-containing transcripts. Nucleic Acids Res. 2020;48:8178–8187. doi: 10.1093/nar/gkaa561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa561</ArticleId><ArticleId IdType="pmc">PMC7430633</ArticleId><ArticleId IdType="pubmed">32619241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Guerrero A., Abrey Recalde M.J., Mangeot P.E., Costa C., Bernadin O., Périan S., Fusil F., Froment G., Martinez-Turtos A., Krug A., et al. Baboon Envelope Pseudotyped "Nanoblades" Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34(+) Cells and Knock-in of AAV6-Encoded Donor DNA in CD34(+) Cells. Front. Genome Ed. 2021;3 doi: 10.3389/fgeed.2021.604371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgeed.2021.604371</ArticleId><ArticleId IdType="pmc">PMC8525375</ArticleId><ArticleId IdType="pubmed">34713246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton J.R., Tsuchida C.A., Nguyen D.N., Shy B.R., McGarrigle E.R., Sandoval Espinoza C.R., Carr D., Blaeschke F., Marson A., Doudna J.A. Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Rep. 2021;35 doi: 10.1016/j.celrep.2021.109207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109207</ArticleId><ArticleId IdType="pmc">PMC8236216</ArticleId><ArticleId IdType="pubmed">34077734</ArticleId></ArticleIdList></Reference><Reference><Citation>Banskota S., Raguram A., Suh S., Du S.W., Davis J.R., Choi E.H., Wang X., Nielsen S.C., Newby G.A., Randolph P.B., et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022;185:250–265.e16. doi: 10.1016/j.cell.2021.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.021</ArticleId><ArticleId IdType="pmc">PMC8809250</ArticleId><ArticleId IdType="pubmed">35021064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu P., Javidi-Parsijani P., Atala A., Lu B. Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient 'hit-and-run' genome editing. Nucleic Acids Res. 2019;47 doi: 10.1093/nar/gkz605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz605</ArticleId><ArticleId IdType="pmc">PMC6753487</ArticleId><ArticleId IdType="pubmed">31299082</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldrup J., Andersen S., Labial A.R.L., Wolff J.H., Frandsen F.P., Skov T.W., Rovsing A.B., Nielsen I., Jakobsen T.S., Askou A.L., et al. Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Res. 2023;51:10059–10074. doi: 10.1093/nar/gkad676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkad676</ArticleId><ArticleId IdType="pmc">PMC10570023</ArticleId><ArticleId IdType="pubmed">37678882</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin J., Zhang X.-Y., Reiser J. Altering the Tropism of Lentiviral Vectors through Pseudotyping. Curr. Gene Ther. 2005;5:387–398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1368960</ArticleId><ArticleId IdType="pubmed">16101513</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Guerrero A., Cosset F.L., Verhoeyen E. Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy. Viruses. 2020;12 doi: 10.3390/v12091016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12091016</ArticleId><ArticleId IdType="pmc">PMC7551254</ArticleId><ArticleId IdType="pubmed">32933033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Schneider I.C., Edes I., Honegger A., Bach P., Schönfeld K., Schambach A., Wels W.S., Kneissl S., Uckert W., Buchholz C.J. T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood. 2012;120:4334–4342. doi: 10.1182/blood-2012-02-412973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-02-412973</ArticleId><ArticleId IdType="pubmed">22898597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender R.R., Muth A., Schneider I.C., Friedel T., Hartmann J., Plückthun A., Maisner A., Buchholz C.J. Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment. PLoS Pathog. 2016;12 doi: 10.1371/journal.ppat.1005641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005641</ArticleId><ArticleId IdType="pmc">PMC4900575</ArticleId><ArticleId IdType="pubmed">27281338</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiken C. Pseudotyping Human Immunodeficiency Virus Type 1 (HIV-1) by the Glycoprotein of Vesicular Stromatitis Virus Targets HIV-1 Entry to an Endocytic Pathway and Suppresses both the Requirement for Nef and the Sensitivity of Cyclosporin A. J. Virol. 1997;71:5871–5877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191842</ArticleId><ArticleId IdType="pubmed">9223476</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelshtein D., Werman A., Novick D., Barak S., Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA. 2013;110:7306–7311. doi: 10.1073/pnas.1214441110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1214441110</ArticleId><ArticleId IdType="pmc">PMC3645523</ArticleId><ArticleId IdType="pubmed">23589850</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche S., Albertini A.A.V., Lepault J., Bressanelli S., Gaudin Y. Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited. Cell. Mol. Life Sci. 2008;65:1716–1728. doi: 10.1007/s00018-008-7534-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-008-7534-3</ArticleId><ArticleId IdType="pmc">PMC11131878</ArticleId><ArticleId IdType="pubmed">18345480</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H., Nie L., et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell. 2020;182:1284–1294.e9. doi: 10.1016/j.cell.2020.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.07.012</ArticleId><ArticleId IdType="pmc">PMC7366990</ArticleId><ArticleId IdType="pubmed">32730807</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., et al. COVID-19 Genomics UK COG-UK Consortium SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409–424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson M.C., Lyddon T.D., Suarez R., Salcedo B., LePique M., Graham M., Ricana C., Robinson C., Ritter D.G. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. J. Virol. 2020;94 doi: 10.1128/JVI.01062-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01062-20</ArticleId><ArticleId IdType="pmc">PMC7565639</ArticleId><ArticleId IdType="pubmed">32788194</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford K.H.D., Eguia R., Dingens A.S., Loes A.N., Malone K.D., Wolf C.R., Chu H.Y., Tortorici M.A., Veesler D., Murphy M., et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses. 2020;12 doi: 10.3390/v12050513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12050513</ArticleId><ArticleId IdType="pmc">PMC7291041</ArticleId><ArticleId IdType="pubmed">32384820</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt F., Weisblum Y., Muecksch F., Hoffmann H.H., Michailidis E., Lorenzi J.C.C., Mendoza P., Rutkowska M., Bednarski E., Gaebler C., et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 2020;217 doi: 10.1084/jem.20201181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201181</ArticleId><ArticleId IdType="pmc">PMC7372514</ArticleId><ArticleId IdType="pubmed">32692348</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281–292.e6. doi: 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Frecha C., Costa C., Negre D., Gauthier E., Russell S.J., Cosset F.L., Verhoeyen E. Stable transduction of quienscent T cells without induction of cycle progession by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood. 2008;112:4843–4852. doi: 10.1182/blood-2008-05-.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-05-</ArticleId><ArticleId IdType="pubmed">18812471</ArticleId></ArticleIdList></Reference><Reference><Citation>Frecha C., Costa C., Lévy C., Nègre D., Russell S.J., Maisner A., Salles G., Peng K.W., Cosset F.L., Verhoeyen E. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood. 2009;114:3173–3180. doi: 10.1182/blood-2009-05-220798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-05-220798</ArticleId><ArticleId IdType="pubmed">19667401</ArticleId></ArticleIdList></Reference><Reference><Citation>Frecha C., Lévy C., Costa C., Nègre D., Amirache F., Buckland R., Russell S.J., Cosset F.L., Verhoeyen E. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J. Virol. 2011;85:5975–5985. doi: 10.1128/JVI.00324-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00324-11</ArticleId><ArticleId IdType="pmc">PMC3126293</ArticleId><ArticleId IdType="pubmed">21450813</ArticleId></ArticleIdList></Reference><Reference><Citation>Noyce R.S., Richardson C.D. Nectin 4 is the epithelial cell receptor for measles virus. Trends Microbiol. 2012;20:429–439. doi: 10.1016/j.tim.2012.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2012.05.006</ArticleId><ArticleId IdType="pubmed">22721863</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L.T., Richardson C.D. The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein. Viruses. 2016;8 doi: 10.3390/v8090250.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8090250</ArticleId><ArticleId IdType="pmc">PMC5035964</ArticleId><ArticleId IdType="pubmed">27657109</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke S., Schneider I.C., Glaser S., Mühlebach M.D., Moritz T., Cattaneo R., Cichutek K., Buchholz C.J. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther. 2009;16:700–705. doi: 10.1038/gt.2009.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2009.11</ArticleId><ArticleId IdType="pubmed">19212424</ArticleId></ArticleIdList></Reference><Reference><Citation>Manchester M., Liszewski M.K., Atkinson J.P., Oldstone M.B. Multiple isoforms of CD46 (membrane cofactor protein) serve as Receptors for Measles Virus. Proc. Natl. Acad. Sci. USA. 1994;91:2161–2165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43330</ArticleId><ArticleId IdType="pubmed">8134365</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu K., Broder C.C., Nikolov D.B. Ephrin-B2 and ephrin-B3 as functional henipavirus receptors. Semin. Cell Dev. Biol. 2012;23:116–123. doi: 10.1016/j.semcdb.2011.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2011.12.005</ArticleId><ArticleId IdType="pmc">PMC3327611</ArticleId><ArticleId IdType="pubmed">22227101</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrete O.A., Levroney E.L., Aguilar H.C., Bertolotti-Ciarlet A., Nazarian R., Tajyar S., Lee B. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature. 2005;436:401–405. doi: 10.1038/nature03838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03838</ArticleId><ArticleId IdType="pubmed">16007075</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernet O., Pohl C., Ainouze M., Kweder H., Buckland R. Nipah virus entry can occur by macropinocytosis. Virology. 2009;395:298–311. doi: 10.1016/j.virol.2009.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.09.016</ArticleId><ArticleId IdType="pubmed">19854459</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomares K., Vigant F., Van Handel B., Pernet O., Chikere K., Hong P., Sherman S.P., Patterson M., An D.S., Lowry W.E., et al. Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo. J. Virol. 2013;87:2094–2108. doi: 10.1128/JVI.02032-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02032-12</ArticleId><ArticleId IdType="pmc">PMC3571488</ArticleId><ArticleId IdType="pubmed">23192877</ArticleId></ArticleIdList></Reference><Reference><Citation>Witting S.R., Vallanda P., Gamble A.L. Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Gene Ther. 2013;20:997–1005. doi: 10.1038/gt.2013.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2013.23</ArticleId><ArticleId IdType="pmc">PMC3839624</ArticleId><ArticleId IdType="pubmed">23698741</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke S., Maisner A., Mühlebach M.D., Koehl U., Grez M., Cattaneo R., Cichutek K., Buchholz C.J. Targeted cell entry of lentiviral vectors. Mol. Ther. 2008;16:1427–1436. doi: 10.1038/mt.2008.128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.128</ArticleId><ArticleId IdType="pmc">PMC3927321</ArticleId><ArticleId IdType="pubmed">18578012</ArticleId></ArticleIdList></Reference><Reference><Citation>Slifka M.K., Antia R., Whitmire J.K., Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 1998;8:363–372.</Citation><ArticleIdList><ArticleId IdType="pubmed">9529153</ArticleId></ArticleIdList></Reference><Reference><Citation>Radbruch A., Muehlinghaus G., Luger E.O., Inamine A., Smith K.G.C., Dörner T., Hiepe F. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 2006;6:741–750. doi: 10.1038/nri1886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1886</ArticleId><ArticleId IdType="pubmed">16977339</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson M.J., Laoharawee K., Lahr W.S., Webber B.R., Moriarity B.S. Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. Sci. Rep. 2018;8 doi: 10.1038/s41598-018-30358-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-30358-0</ArticleId><ArticleId IdType="pmc">PMC6092381</ArticleId><ArticleId IdType="pubmed">30108345</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung K.L., Meitlis I., Hale M., Chen C.Y., Singh S., Jackson S.W., Miao C.H., Khan I.F., Rawlings D.J., James R.G. Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells. Mol. Ther. 2018;26:456–467. doi: 10.1016/j.ymthe.2017.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.11.012</ArticleId><ArticleId IdType="pmc">PMC5835153</ArticleId><ArticleId IdType="pubmed">29273498</ArticleId></ArticleIdList></Reference><Reference><Citation>Laoharawee K., Johnson M.J., Moriarity B.S. CRISPR/Cas9-Mediated Genome Engineering of Primary Human B Cells. Methods Mol. Biol. 2020;2115:435–444. doi: 10.1007/978-1-0716-0290-4_24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0290-4_24</ArticleId><ArticleId IdType="pubmed">32006415</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffett H.F., Harms C.K., Fitzpatrick K.S., Tooley M.R., Boonyaratanakornkit J., Taylor J.J. B cells engineered to express pathogen-specific antibodies protect against infection. Sci. Immunol. 2019;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6913193</ArticleId><ArticleId IdType="pubmed">31101673</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahmad A.D., Raviv Y., Horovitz-Fried M., Sofer I., Akriv T., Nataf D., Dotan I., Carmi Y., Burstein D., Wine Y., et al. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nat. Commun. 2020;11:5851. doi: 10.1038/s41467-020-19649-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19649-1</ArticleId><ArticleId IdType="pmc">PMC7673991</ArticleId><ArticleId IdType="pubmed">33203857</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahmad A.D., Lazzarotto C.R., Zelikson N., Kustin T., Tenuta M., Huang D., Reuveni I., Nataf D., Raviv Y., Horovitz-Fried M., et al. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat. Biotechnol. 2022;40:1241–1249. doi: 10.1038/s41587-022-01328-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01328-9</ArticleId><ArticleId IdType="pmc">PMC7613293</ArticleId><ArticleId IdType="pubmed">35681059</ArticleId></ArticleIdList></Reference><Reference><Citation>Giroglou T., Cinatl J., Jr., Rabenau H., Drosten C., Schwalbe H., Doerr H.W., von Laer D. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J. Virol. 2004;78:9007–9015. doi: 10.1128/JVI.78.17.9007-9015.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.17.9007-9015.2004</ArticleId><ArticleId IdType="pmc">PMC506966</ArticleId><ArticleId IdType="pubmed">15308697</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu J., Plante K.S., Plante J.A., Xie X., Zhang X., Ku Z., An Z., Scharton D., Schindewolf C., et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature. 2022;602:294–299. doi: 10.1038/s41586-021-04245-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04245-0</ArticleId><ArticleId IdType="pmc">PMC8900207</ArticleId><ArticleId IdType="pubmed">34818667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozog S., Chen C.X., Simpson E., Garijo O., Timberlake N.D., Minder P., Verhoeyen E., Torbett B.E. CD46 Null Packaging Cell Line Improves Measles Lentiviral Vector Production and Gene Delivery to Hematopoietic Stem and Progenitor Cells. Mol. Ther. Methods Clin. Dev. 2019;13:27–39. doi: 10.1016/j.omtm.2018.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2018.11.006</ArticleId><ArticleId IdType="pmc">PMC6310745</ArticleId><ArticleId IdType="pubmed">30603655</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert J.M., Frecha C., Amirache Bouafia F., N'Guyen T.H., Boni S., Cosset F.L., Verhoeyen E., Halary F. Measles virus glycoprotein-pseudotyped lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic modification of monocyte-derived dendritic cells. J. Virol. 2012;86:5192–5203. doi: 10.1128/JVI.06283-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06283-11</ArticleId><ArticleId IdType="pmc">PMC3347358</ArticleId><ArticleId IdType="pubmed">22345444</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard-Gagnepain A., Amirache F., Costa C., Lévy C., Frecha C., Fusil F., Nègre D., Lavillette D., Cosset F.L., Verhoeyen E. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood. 2014;124:1221–1231. doi: 10.1182/blood-2014-02-.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-02-</ArticleId><ArticleId IdType="pubmed">24951430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangeot P.E., Risson V., Fusil F., Marnef A., Laurent E., Blin J., Mournetas V., Massouridès E., Sohier T.J.M., Corbin A., et al. Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat. Commun. 2019;10:45. doi: 10.1038/s41467-018-07845-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07845-z</ArticleId><ArticleId IdType="pmc">PMC6318322</ArticleId><ArticleId IdType="pubmed">30604748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton J.R., Chen E., Perez B.S., Sandoval Espinoza C.R., Kang M.H., Trinidad M., Ngo W., Doudna J.A. In vivo human T cell engineering with enveloped delivery vehicles. Nat. Biotechnol. 2024 doi: 10.1038/s41587-023-02085-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-023-02085-z</ArticleId><ArticleId IdType="pmc">PMC11236958</ArticleId><ArticleId IdType="pubmed">38212493</ArticleId></ArticleIdList></Reference><Reference><Citation>Maule G., Arosio D., Cereseto A. Gene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing. Int. J. Mol. Sci. 2020;21 doi: 10.3390/ijms21113903.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21113903</ArticleId><ArticleId IdType="pmc">PMC7313467</ArticleId><ArticleId IdType="pubmed">32486152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T., Peng K.W., Harvey M., Greiner S., Lorimer I.A.J., James C.D., Russell S.J. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 2005;23:209–214. doi: 10.1038/nbt1060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1060</ArticleId><ArticleId IdType="pubmed">15685166</ArticleId></ArticleIdList></Reference><Reference><Citation>Anliker B., Abel T., Kneissl S., Hlavaty J., Caputi A., Brynza J., Schneider I.C., Münch R.C., Petznek H., Kontermann R.E., et al. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat. Methods. 2010;7:929–935. doi: 10.1038/nmeth.1514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1514</ArticleId><ArticleId IdType="pubmed">20935652</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamva E., Ozog S., Verhoeyen E., James R.G., Rawlings D.J., Torbett B.E. An optimized measles virus glycoprotein-pseudotyped lentiviral vector production system to promote efficient transduction of human primary B cells. STAR Protoc. 2022;3 doi: 10.1016/j.xpro.2022.101228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2022.101228</ArticleId><ArticleId IdType="pmc">PMC8914380</ArticleId><ArticleId IdType="pubmed">35284833</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy C., Amirache F., Costa C., Frecha C., Muller C.P., Kweder H., Buckland R., Cosset F.L., Verhoeyen E. Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells. Mol. Ther. 2012;20:1699–1712. doi: 10.1038/mt.2012.96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2012.96</ArticleId><ArticleId IdType="pmc">PMC3437580</ArticleId><ArticleId IdType="pubmed">22617109</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneissl S., Abel T., Rasbach A., Brynza J., Schneider-Schaulies J., Buchholz C.J. Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS One. 2012;7 doi: 10.1371/journal.pone.0046667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046667</ArticleId><ArticleId IdType="pmc">PMC3468630</ArticleId><ArticleId IdType="pubmed">23071609</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers G.L., Cannon P.M. Genome edited B cells: a new frontier in immune cell therapies. Mol. Ther. 2021;29:3192–3204. doi: 10.1016/j.ymthe.2021.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.09.019</ArticleId><ArticleId IdType="pmc">PMC8571172</ArticleId><ArticleId IdType="pubmed">34563675</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo B., Zhan Y., Luo M., Dong H., Liu J., Lin Y., Zhang J., Wang G., Verhoeyen E., Zhang Y., Zhang H. Engineering of alpha-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration. Cell Death Dis. 2020;11:973. doi: 10.1038/s41419-020-03187-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03187-1</ArticleId><ArticleId IdType="pmc">PMC7661525</ArticleId><ArticleId IdType="pubmed">33184267</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Schneider I.C., Gallet M., Kneissl S., Buchholz C.J. Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM. Virology. 2011;413:149–152. doi: 10.1016/j.virol.2011.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.02.010</ArticleId><ArticleId IdType="pubmed">21470651</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano K.A., Wong A.A.L., Brown R., Situ K., Chua B.A., Abu A.E., Pham T.T., Reyes G.C., Ramachandran S., Kamata M., et al. Envelope protein-specific B cell receptors direct lentiviral vector tropism in vivo. Mol. Ther. 2024;32:1311–1327. doi: 10.1016/j.ymthe.2024.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2024.03.002</ArticleId><ArticleId IdType="pmc">PMC11081870</ArticleId><ArticleId IdType="pubmed">38449314</ArticleId></ArticleIdList></Reference><Reference><Citation>An M., Raguram A., Du S.W., Banskota S., Davis J.R., Newby G.A., Chen P.Z., Palczewski K., Liu D.R. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat. Biotechnol. 2024 doi: 10.1038/s41587-023-02078-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-023-02078-y</ArticleId><ArticleId IdType="pmc">PMC11228131</ArticleId><ArticleId IdType="pubmed">38191664</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkman E.K., Chen T., Amendola M., van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42:e168. doi: 10.1093/nar/gku936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku936</ArticleId><ArticleId IdType="pmc">PMC4267669</ArticleId><ArticleId IdType="pubmed">25300484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiau T., Conant D., Maures T., Waite K., Yang J., Kelso R., Holden K., Enzmann B.L., Stoner R. Inference of CRISPR Edits from Sanger Trace Data. CRISPR J. 2022;5:123–130. doi: 10.1101/251082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/251082</ArticleId><ArticleId IdType="pubmed">35119294</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>